ARHGEF5 and lung cancer: High levels of kinase insert domain receptor (KDR) along with its ligand, vascular endothelial growth factor A (VEGFA), have been associated with shorter survival times in lung cancer patients due to their effects on cell proliferation [43], as has been ARHGEF5, which leads to cell invasion and tumor growth via Akt pathway [44].